Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share was 4.3% below analysts’ consensus estimates.
Is now the time to buy AbbVie? Find out in our full research report .
AbbVie (ABBV) Q4 CY2024 Highlights:
"2024 was a year of significant progress for AbbVie. Our growth platform delivered outstanding results, we advanced our pipeline with key regulatory approvals and promising data, and we strengthened our business through strategic transactions," said Robert A. Michael, CEO of AbbVie.
Company Overview
Founded in 2013 as a spin-off from Abbott Laboratories (NYSE:ABT), AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and sells prescription medicines focused on areas like immunology (arthritis, for example), oncology (cancers), and neuroscience (depression, for example).
Therapeutics
Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.
Sales Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, AbbVie grew its sales at a decent 8.6% compounded annual growth rate. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. AbbVie’s recent history marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 1.5% over the last two years.
AbbVie also reports sales performance excluding currency movements, which are outside the company’s control and not indicative of demand. Over the last two years, its constant currency sales were flat. Because this number is better than its normal revenue growth, we can see that foreign exchange rates have been a headwind for AbbVie.
This quarter, AbbVie reported year-on-year revenue growth of 5.6%, and its $15.1 billion of revenue exceeded Wall Street’s estimates by 1.9%.
Looking ahead, sell-side analysts expect revenue to grow 5% over the next 12 months, an improvement versus the last two years. This projection is above average for the sector and indicates its newer products and services will catalyze better top-line performance.
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next .
Adjusted Operating Margin
AbbVie has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 47.6%.
Analyzing the trend in its profitability, AbbVie’s adjusted operating margin decreased by 4.6 percentage points over the last five years. This performance was caused by more recent speed bumps as the company’s margin fell by 8.1 percentage points on a two-year basis. We’re disappointed in these results because it shows operating expenses were rising and it couldn’t pass those costs onto its customers.
in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.
AbbVie’s EPS grew at an unimpressive 2.4% compounded annual growth rate over the last five years, lower than its 8.6% annualized revenue growth. This tells us the company became less profitable on a per-share basis as it expanded.
We can take a deeper look into AbbVie’s earnings to better understand the drivers of its performance. As we mentioned earlier, AbbVie’s adjusted operating margin declined by 4.6 percentage points over the last five years. Its share count also grew by 19.4%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders.
In Q4, AbbVie reported EPS at $2.16, down from $2.80 in the same quarter last year. This print missed analysts’ estimates. Over the next 12 months, Wall Street expects AbbVie’s full-year EPS of $10.13 to grow 21.1%.
Key Takeaways from AbbVie’s Q4 Results
We were impressed by how significantly AbbVie blew past analysts’ constant currency revenue expectations this quarter. We were also happy its 2025 EPS guidance outperformed Wall Street’s estimates. Overall, this quarter had some key positives. The stock traded up 5.3% to $184.84 immediately after reporting.
Big picture, is AbbVie a buy here and now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free .